IRCT20200523047550N1已完成3 期
Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients diagnosed with COVID-19 infection based on PCR test for oropharyngeal and nasopharyngeal secretions or specific lung involvement in chest CT
- •Age over 18 years
- •The patient has PO tolerance
- •Gaining conscious satisfaction from the patient or first-degree relatives responsible for the patient
- •No pregnancy and breastfeeding
排除标准
- •Alt more than five times normal
- •Renal failure
- •History of any drug allergies
- •Pregnancy and lactation
- •Use of antiarrhythmic drugs
研究者
相似试验
招募中
3 期
Evaluating the effects of Umifenovir (Arbidol) in COVID-19IRCT20151227025726N15Shahid Beheshti University of Medical Sciences100
已完成
3 期
mifenovir effectiveness in the treatment of COVID-19IRCT20200322046833N1Center for Progress and Development of Iran100
招募中
3 期
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19IRCT20080901001165N46Center for Progress and Development of Iran200
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
招募中
3 期
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60